drugset
drugset / Trial / NCT04318015

Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)

NCT04318015 ↗

Phase 3 Completed 289 enrolled National Institute of Respiratory Diseases, Mexico
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients.

Timeline

Start
2020-04-14
Primary completion
2020-12-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 200 mg Oral

Indications

COVID-19 severe acute respiratory syndrome